Barclays PLC In8 Bio, Inc. Transaction History
Barclays PLC
- $353 Billion
- Q1 2025
Shares
1 transactions
Others Institutions Holding INAB
# of Institutions
25Shares Held
19.9MCall Options Held
0Put Options Held
0-
Bios Capital Management, LP Fort Worth, TX8.6MShares$18.6 Million1.8% of portfolio
-
Franklin Resources Inc San Mateo, CA5.7MShares$12.3 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.08MShares$4.49 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.8MShares$3.89 Million0.0% of portfolio
-
Sigma Planning Corp Ann Arbor, MI701KShares$1.51 Million0.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $52.9M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...